The therapeutic effect of rilotumumab in CRC has also been evaluated in a randomized phase Ib/II research where panitumumab (a monoclonal antibody targeting EGFR) was combined with rilotumumab or placebo in patients with kirsten rat sarcoma (KRAS) wild-type metastatic CRC who met the prespecified criterion for improvement in ORR (Van Cutsem et al., 2014). This evidence concerns the gene EGFR and colorectal carcinoma.